NEW YORK, July 18, 2017 /PRNewswire/ --
If you want a Stock Review on EBIO, EGLT, GNMX or INSY then come over to
On Monday, shares in Cambridge, Massachusetts-based Eleven Biotherapeutics Inc. recorded a trading volume of 307,297 shares, which was above their three months average volume of 264,730 shares. The stock ended the session 5.23% higher at $1.61. The Company's shares have gained 16.67% in the last one month. The stock is trading 5.80% above its 50-day moving average. Moreover, shares of Eleven Biotherapeutics, which focuses on the design and development of targeted protein therapeutics, have a Relative Strength Index (RSI) of 58.79. The free research report on EBIO is available at: http://dailystocktracker.com/registration/?symbol=EBIO
Wayne, Pennsylvania headquartered Egalet Corp.'s stock closed the day flat at $1.44 with a total trading volume of 534,669 shares. The Company's shares are trading 41.81% below their 50-day moving average. Shares of the Company, which develops, manufactures, and commercializes treatments for patients with pain and other conditions, have an RSI of 31.23.
On July 11th, 2017, Egalet announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock and accompanying warrants to purchase up to 16,666,667 shares, at a combined public offering price of $1.80 per share and accompanying warrant. The aggregate gross proceeds from this offering are expected to be approximately $30.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses, payable by the Company. The complimentary report on EGLT can be downloaded at: http://dailystocktracker.com/registration/?symbol=EGLT
Aevi Genomic Medicine
Shares in Wayne, Pennsylvania-based Aevi Genomic Medicine Inc. recorded a trading volume of 121,341 shares. The stock ended yesterday's trading session 0.75% lower at $1.32. The Company's shares have advanced 3.94% in the past month. The stock is trading slight below its 50-day moving average by 0.02%. Furthermore, shares of Aevi Genomic Medicine, which engages in the research and development of products in the field of biotechnology and associated medical equipment in the US, have an RSI of 51.20. Visit us today and download our complete research report on GNMX for free at: http://dailystocktracker.com/registration/?symbol=GNMX
Chandler, Arizona headquartered INSYS Therapeutics Inc.'s stock finished Monday's session 1.98% higher at $12.39 with a total trading volume of 450,787 shares. The Company's shares have advanced 9.36% in the last one month, 17.22% over the previous three months, and 34.67% since the start of this year. The stock is trading above its 200-day moving average by 9.13%. Additionally, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have an RSI of 48.30.
On June 20th, 2017, INSYS Therapeutics announced the addition of four, pharmaceutical industry veterans to its management team. Joining the Company are Brian Jennings, Vice President of Sales; Dr. Dean Mariano, Senior Director, Clinical Development/Medical Affairs; Ariyapadi (Krishna) Krishnaraj, Vice President of Marketing and Managed Care; and Scott Warlick, General Manager, Manufacturing. Get free access to your technical report on INSY at: http://dailystocktracker.com/registration/?symbol=INSY
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All